Fix The Patent Laws

The Union for Affordable Cancer Treatment comments on SA’s Draft IP Policy

Posted on | October 10, 2017 | No Comments

UACT-300dpi-300pxOn October 10, 2017, the Union for Affordable Cancer Treatment (UACT) and 22 NGOs working on cancer in South Africa and members of the Cancer Alliance, submitted comments to the South Africa on the Draft South Africa IP Policy.

The text of the submission can be read here and below.


October 10, 2017

The Honorable Dr. Rob Davies Minister of Trade and Industry 77 Meintjies Street Sunnyside, Pretoria, Gauteng, South Africa

Re: Draft National Policy on Intellectual Property

Dear Minister Davies,

We write to you on behalf of the Union for Affordable Cancer Treatment (UACT), a union of people affected by cancer, their family members and friends, people who take care of people with cancer, health care professionals and cancer researchers committed to increasing access to effective cancer treatment and care. UACT is particularly concerned about the rapidly escalating cost of cancer medication and seeks to fight for cancer treatment and care to be affordable and available, everywhere, for everyone who needs it.

UACT wishes to offer some brief comments on the Draft Intellectual Property Policy of the Republic of South Africa, Phase I 2017, specifically with regard to IP and health. We appreciate that the draft takes positive steps but would like to see South Africa go further in implementing policies that make “access to medicines for all” a reality.

There are many proposals in the policy that we were pleased to see, including:

  • Recommendations on the introduction of a substantive search and examination (SSE) approach; improved patent opposition mechanisms; and the adoption of patentability criteria “that address the country’s public health and environmental concerns, as well as industrial policy objectives.”
  • Positive language on the important role of voluntary licensing, with particular emphasis on the transparency of terms and conditions in such licenses as exemplified by the Medicines Patent Pool.
  • Recommendations on the use of compulsory licensing reflecting steps needed to make the process more streamlined and less encumbered by a litigation process; government use licenses as a viable legal tool relevant to the state’s obligation “to take reasonable legislative and other measures to progressively realize the right to have access to health care services…[including] the utilization of TRIPS flexibilities such as Article 31 (b), in full accordance with South African law;” and engaging with WTO to streamline the cumbersome Paragraph 6 mechanism on compulsory licensing for export.
  • Recognition of the importance of multilateral cooperation, particularly noting the work at the WHO on addressing “issues such as lack of affordability, limited research where market returns are small or uncertain . . “   and noting delinkage as among the core principles of the WHO Consultative Expert Working Group.

UACT notes the use of TRIPS flexibilities and the principle of delinkage were recommended as key strategies to improve policy coherence in the UN’s 2030 Agenda for Sustainable Development and in the 2016 Report of the UN High Level Panel on Access to Medicines.

UACT is concerned that South Africa has not acted to induce non-voluntary licensing of drug patents since 2003 in the Hazel Tau case, and that case involved the independent RSA Competition Commission, rather than an executive agency.

While we applaud and support the idea of streamlining the process, we also suggest the grounds for licensing should include some that are mandatory, so the compulsory licensing process is self executing when a need is presented.  One benefit of a mandatory compulsory licensing ground is that the RSA government officials could not be pressured or lobbied to withhold a license, since the policy to issue the compulsory license was automatic if the grounds themselves are satisfied.  An example of a mandatory non-voluntary authorization is the U.S. U.S. Biologics Price Competition and Innovation Act of 2009, which eliminates the possibility of an injunction for infringement when the patent holder fails to provide timely constructive disclosure of the patent landscape on biologic drugs, or Section 92A of India’s patent law, which provides that

“Compulsory licence shall be available for manufacture and export of patented pharmaceutical products to any country having insufficient or no manufacturing capacity in the pharmaceutical sector for the concerned product to address public health problems. . . ”  [emphasis added].

Here we suggest one of two approaches for consideration.  The first is a non-voluntary authorization to use an invention in the context of Article 31 of the WTO TRIPS agreement:

Option 1, as an exception to the exclusive right

Non-voluntary use of patented invention in the field of use of a drug, vaccine or other medical technology shall be allowed, subject to the payment of a reasonable and affordable royalty, whenever a drug or vaccine is not available at a price that is reasonable and/or affordable for the general population or any significant group of potential patients, and there is evidence that access is limited due to the price.  A decision that the price for a product is not generally reasonable and/or affordable can be made either by the Ministry of Health, the premiers of any provinces, the South Africa Competition Commission, or by any judge in a lower court.

The second approach is similar, except that it is framed as a limitation on remedies, under Article 44.2 of the TRIPS.  The advantage of the second approach is that avoids the restrictions in the WTO relating to Article 31 of the TRIPS, such as a requirement for prior negotiation on reasonable commercial terms and condition, and it does not limit exports.  The limitation on remedies is the approach taken in the U.S government use statute (35 USC 1498) and the U.S. Biologics Price Competition and Innovation Act of 2009 and the dozens of compulsory license that have been issued in the United States by the courts in the context of the enforcement of infringements.

Option 2, as a limitation on the remedies for infringement

The remedies for infringement of a patent on an invention in the field of use of a drug, vaccine or other medical technology shall be be limited to the payment of a reasonable and affordable royalty, whenever a drug or vaccine is not available at a price that is reasonable and/or affordable for the general population or any significant group of potential patients, and there is evidence that access is limited due to the price.  A decision that the price for a product is not generally reasonable and/or affordable can be made either by the Ministry of Health, the premiers of any provinces, the South Africa Competition Commission, or by any judge in a lower court.

We believe option 2 is best, although either approach would be a vast improvement on the current law.

In addition, as part of the streamlining of the procedures, UACT recommends South Africa adopt royalty guidelines for non-voluntary licenses, considering, for example, the 2005 WHO and UNDP royalty guidelines as a model.

One of the topics not discussed in the Draft Policy concerns transparency, particularly as it relates to the management of intellectual property rights and the economic factors that are relevant to the pricing of medicines, vaccines and other medical technologies.   As one country, the RSA has limits on the leverage it can exercise to ensure transparency, but there are measures it can take, and the government can also work with others in fora such as the World Health Organization to promote standards on transparency.

At a national level, the RSA could require the following transparency measures,  all of which are designed to public and to benefit and inform the general public.

  1. An annual reporting of  yearly and cumulative sales earned by every drug or vaccine registered for sale in the RSA market that does not face competition from a generic product.
  2. For each new drug registered in the RSA, the amount of money spent on each clinical trial used to justify the registration of the drug, and all public subsidies including tax credits that were relevant to each trial.
  3. The patent asserted for every drug or vaccine, including an explanation of how each patent is relevant to the drug, making a failure to disclose sanctioned by an elimination of damages or inductions, as in the U.S. Biologics Price Competition and Innovation Act of 2009.
  4. Require transparency of all royalty patents on patents granted in RSA to patent holders.
  5. Require all patient assistance programs in South Africa to provide information on the criteria for assistance, the number of requests and the number persons receiving the assistance.
  6. For drugs or vaccines where there is a public interest in ensuring adequate access, the Ministry of Health should be allowed to require the manufacturer to disclose the units sold in the RSA.

On the topic of delinkage, South Africa should consider working with key partners to encourage the World Health Organization, UNITAID or another body to undertake a study of the feasibility of delinking prices for cancer from R&D costs, and proposal that was debated during the 2017 World Health Assembly in the resolution on cancer.

We welcome the opportunity to engage in further dialogue with your government as you continue to work on these issues.

Sincerely and Respectfully submitted,

Manon Anne Ress, PhD, Acting Director and co-founder, UACT

Catherine Tomlinson, Member, UACT Board of Directors

Kirsten Myhr, MScPharm, MPH, Member, UACT Board of Directors

James Love, Member, UACT Board of Directors

Ellen F. M. ‘t Hoen, LLM, Chair, UACT Expert Advisory Committee

Gilberto de Lima Lopes Junior, MD, MBA, FAMS, Member, UACT Expert Advisory Board

Ruth Lopert, MD, MMedSc,  FAFPHM, Member, UACT Expert Advisory Board

Ophira Ginsburg, MD, Member, UACT Expert Advisory Board

Leena Menghaney, Member, UACT Expert Advisory Board

Ilze Aizsilniece, Member, UACT Organizing Committee

Salomé Meyer (Independent Cancer Advocate)

The following Health NGOs working on cancer in South Africa

  1. Amabele Belles’ Project Flamingo (link)
  2. Breast Health Foundation (BHF) (link)
  3. The Cancer Association of South Africa (CANSA) (link)
  4. Childhood Cancer Foundation South Africa (CHOC) (link)
  5. Can-Sir (link)
  6. CanSurvive (link)
  7. Care for Cancer Foundation (link)
  8. Hospice Palliative Care Association (HPCA) (link)
  9. IGAZI Foundation (link)
  10. Look Good Feel Better (link)
  11. Lymphoedema Association of South Africa (LAOSA) (link)
  12. Movember/The Men’s Foundation (link)
  13. NONSA
  14. Pancreatic Cancer Action Network South Africa (PanCAN) (link)
  15. Pocket Cancer Support (link)
  16. People Living with Cancer (PLWC) (link)
  17. Pink Trees for Pauline (link)
  18. Rainbows and Smiles (link)
  19. Reach for Recovery (link)
  20. The Sunflower Fund (link)
  21. Vrede Foundation (link)
  22. Wings for Hope (link)

Cc:

  • Dr Aaron Motsoaledi, Minister of Health
  • Naledi Pandor, Minister of Science and Technology
  • Malebona Precious Matsoso, Director-General, Department of Health
  • Marumo Nkomo, Director: Legal – International Trade & Investment, Department of Trade and Industry
  • Interministerial Committee, via  ippolicy2017@thedti.gov.za

 

Comments

Leave a Reply





  • About the Campaign

    fix the patent laws
    Fix the Patent Laws is a campaign of the Treatment Action Campaign (TAC). TAC is a non-profit organisation that seeks to ensure that every person living with HIV has access to quality, comprehensive prevention and treatment services to live a healthy life. Through this blog we will highlight how amending South Africa’s Patents Act 57 of 1978 will reduce the cost of medicines, improving the health and saving the lives of millions of South Africans.

  • Read the TAC and MSF campaign pamphlet

  • Latest tweets